𝔖 Bobbio Scriptorium
✦   LIBER   ✦

40 KDA peginterferon alfa-2A (PEGASYS®) can be administered safely in patients with end-stage renal disease: Matthew W Lamb, Ian M Marks, Lucy Wynohradnyk, Roche Laboratories Inc, Nutley, NJ; Marlene W Modi, Hoffmann-La Roche Inc, Nutley, NJ; Richard A Preston, University of Miami, Miami, FL; S. Chris Pappas, Roche Laboratories Inc, Nutley, NJ

Book ID
118688998
Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
200 KB
Volume
34
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

40 kDa peginterferon alfa-2A (PEGASYS®)
40 kDa peginterferon alfa-2A (PEGASYS®) in post-liver transplant recipients with established recurrent hepatitis C: preliminary results of a randomized multicenter trial: Peter Ferenci, Markus Peck-Radosavljevic, University of Vienna, Wien Austria; Wolfgang Vogel, Ivo Graziadei, Medical University, Innsbruck, Innsbruck Austria; Caroline Riely, University of Tennessee, Memphis, TN; Michael D Voigt, University of Iowa, Iowa City, IA; Ian M Marks, Richard Cambron, Lucy Wynohradnyk, S Chris Pappas, Roche Laboratories Inc, Nutley, NJ
📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB
40 kDa peginterferon alfa-2A (PEGASYS®)
40 kDa peginterferon alfa-2A (PEGASYS®) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT): preliminary results of a randomized multicenter trial: Cosme Manzarbeitia, Albert Einstein Medical Center, Philadelphia, PA; Lewis Tepermann, New York University Medical Center, New York, NY; Naga Chalasani, Indiana University Medical Center, Indianapolis, IN; Patricia Sheiner, Mount Sinai Medical Center, New York, NY; Russel Wiesner, The Mayo Clinic, Rochester, MN; Ian M Marks, Lucy Wynohradnyk, S. Chris Pappas, Roche Laboratories Inc, Nutley, NJ
📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB